FDA clears way for Sarepta Therapeutics to use Duchenne drug in some patients | NYGazet

The agency said in a statement that the "voluntary hold" on the treatment for older patients remains in effect.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam... [567 chars]